Know Cancer

forgot password

STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)

Phase 2
18 Years
Open (Enrolling)
Non-small Cell Lung Cancer (NSCLC)

Thank you

Trial Information

STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)

This study evaluates the effect of adjuvant chemotherapy in patients who received treatment
with stereotactic radiation for early stage lung cancer and who are at high risk for
microscopic metastatic disease.

Chemotherapy in the form of cisplatin/docetaxel or cisplatin/pemetrexed will be administered
approximately six weeks after Stereotactic Body Radiation Therapy (SBRT). Patients will
then undergo follow up clinical evaluation and imaging to evaluate treatment response and
for surveillance.

A patient population of 65 patients will be required. Enrollment in this protocol is planned
by multi center involvement in the state of Kentucky as part of the Kentucky Trial Network

Inclusion Criteria:

- Age ≥ 18 years

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Histologically diagnosed non-small cell lung cancer(NSCLC, cT1-T3 (<= 5cm) (AJCC
7ed). The following histologies are eligible: squamous cell carcinoma,
adenocarcinoma, large cell carcinoma, large cell neuroendocrine, or non-small cell
carcinoma not otherwise specified; bronchioloalveolar cell carcinoma is a subtype of
NSCLC but will be excluded from this study because assessment of multifocal disease
spread through the airways is difficult.

- Required CT of the chest and abdomen with contrast unless medically contraindicated
(evaluating both lungs, mediastinum, liver, and adrenals) and Whole Body Positron
Emission Tomography (PET) for staging. An integrated PET/Computed Tomography (CT)
will meet the CT and PET requirements for staging. Images must be read by a trained
radiologist and performed 8 weeks prior to initiation of treatment. PET imaging must
allow adequate visualization of the primary tumor, draining lymphatics in hilar and
mediastinum, adrenals, and skeleton.

Note: Per Radiation Therapy Oncology Group (RTOG) 0915 inclusion criteria, patients with
hilar or mediastinal lymph nodes ≤ 1cm and no abnormal hilar or mediastinal uptake on PET
will be considered N0. Patients with > 1 cm hilar or mediastinal lymph nodes on CT or
abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if
directed tissue biopsy of all abnormally identified areas are negative for cancer.

- Deemed medically inoperable by an experienced thoracic cancer clinician for a
standard lobectomy and lymph node sampling/dissection. Inoperability may be defined
utilizing a number of criteria. These include any of the following:

- Pretreatment Forced Expiratory Volume (FEV1) < 40% predicted

- Postoperative FEV1 < 30% predicted

- Severely reduced diffusion capacity

- Baseline hypoxemia and/or hypercapnia

- Exercise oxygen consumption < 50% predicted

- Severe pulmonary hypertension

- Diabetes mellitus with severe end organ damage

- Severe cerebral, cardiac, or peripheral vascular disease

- Decline surgery after evaluation by a thoracic surgeon

Required laboratory values within 2 weeks of chemotherapy initiation

- Absolute neutrophil count (ANC) ≥ 1500 mm3

- Platelets ≥ 100,000/mm3

- Total Bilirubin ≤ 1.5 mg/dL

- Serum glutamic oxaloacetic transaminase (SGOT)- aspartate aminotransferase (AST) < 5
x upper limit of normal (ULN}

- Serum glutamic pyruvic transaminase (SGPT)- alanine transaminase(ALT) < 5 x
upper limit of normal (ULN)

- Serum Creatinine ≤ 1.5 x institutional upper limit of normal (ULN)

- For patients assigned to pemetrexed/Cisplatin therapy calculated Creatinine Clearance
(CrCl) must be obtained within 2 weeks of randomization and calculated CrCl must be >
45mL/min using the standard Cockcroft and Gault formula

Exclusion Criteria:

- Primary lesion size not within the acceptable criteria

- Evidence of regional metastases or distant metastases following appropriate staging

- Previous radiation to the chest

- Chemotherapy within the previous five years

- Previous surgery for this particular lung tumor

- Plans for concomitant chemotherapy with radiation

- Active systemic or pulmonary infection

- Pregnant or lactating females

- Synchronous primary malignancy or prior malignancy in the past 2 years except for
invasive malignancy that has been treated definitively and the patient remains
disease free for > 3 years with life expectancy > 3 years. Previous skin cancers and
carcinoma in situ treated definitively are acceptable.

- Patients assigned to pemetrexed/cisplatin therapy must NOT have squamous cell

- Bronchioloalveolar cell carcinoma is excluded because assessment of multifocal
disease spread through the airways is difficult

- Receipt of any other investigational agents or participation in any other
investigational drug study within 4 weeks preceding initiation of study treatment

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To measure the feasibility of adjuvant chemotherapy after stereotactic body radiation therapy for early stage non-small cell lung cancer (NSCLC)

Outcome Time Frame:

3 years after subject enrollment

Safety Issue:


Principal Investigator

Goetz H Kloecker, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

James Graham Brown Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

February 2011

Completion Date:

February 2015

Related Keywords:

  • Non-Small Cell Lung Cancer (NSCLC)
  • lung cancer
  • radiation
  • stereotactic
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



James Graham Brown Cancer CenterLouisville, Kentucky  40202